e-learning
resources
Munich 2014
Sunday, 07.09.2014
Asthma and COPD management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies
D. Price, M. Thomas, R. Lamarca, E. Garcia Gil (Aberdeen, Southampton, United Kingdom; Barcelona, Spain)
Source:
International Congress 2014 – Asthma and COPD management
Session:
Asthma and COPD management
Session type:
Thematic Poster Session
Number:
892
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Price, M. Thomas, R. Lamarca, E. Garcia Gil (Aberdeen, Southampton, United Kingdom; Barcelona, Spain). Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies. Eur Respir J 2014; 44: Suppl. 58, 892
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD
Source: International Congress 2014 – Markers
Year: 2014
Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Dissociation between clinical trial inclusion and exclusion criteria for trials in severe asthma and the reality of the patient population
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPDÔ trial
Source: Annual Congress 2011 - COPD management
Year: 2011
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
Source: International Congress 2014 – Clinical presentations
Year: 2014
Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept